Samsung Bioepis confirms it filed biosimilar Enbrel in EU
This article was originally published in Scrip
Samsung Bioepis has confirmed that it filed the biosimilar version of Amgen's TNF-inhibitor Enbrel (etanercept) that is now being assessed by the European Medicines Agency's scientific committee, the CHMP.
You may also be interested in...
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.